首药控股：RET抑制剂索特替尼片新药上市申请获得受理，用于治疗非小细胞肺癌

Core Viewpoint - The announcement by Shouyao Holdings regarding the acceptance of the new drug application (NDA) for SY-5007, a selective RET tyrosine kinase inhibitor, marks a significant milestone in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with RET gene fusion positivity [1] Group 1 - SY-5007 is a fully self-developed drug by the company and is the first selective RET inhibitor to enter clinical research with rapid clinical progress [1] - The drug has demonstrated significant and durable efficacy in both treatment-naive and previously treated patients with RET fusion-positive non-small cell lung cancer [1] - SY-5007 exhibits good safety and tolerability profiles, making it a promising option for patients [1]